Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.

Inclusion Criteria: * Must have met the inclusion criteria for preceding double-blind study * Must have received pregabalin or amitriptyline or placebo under double-blind conditions under double-blind conditions at least during first 3 weeks if double-blind treatment phase of preceding study. Exclusion Criteria: * Patients cannot be included if they experienced a serious adverse event while participating in preceding double-blind study, which was determined to be related to the study medication.